Home Reimbursed medicines Risankizumab

Risankizumab — maximum prices and reimbursement

The CANAMED catalogue contains 8 medicines with the active substance Risankizumab, from 2 manufacturers. Below you can see each entry with the brand name, the manufacturer, the maximum retail price, the reimbursement percentage and the prescription status — plus live pharmacy prices, where we track them.

8 CANAMED entries
2 Manufacturers
10417.91–22026.09 Maximum price (RON)
4 With a reimbursement percentage
Search live prices → All reimbursed medicines →

In short: for the active substance Risankizumab there are 8 authorised medicines in the CANAMED catalogue, with maximum retail prices between 10417.91 and 22026.09 RON, from 2 manufacturers. For 4 of them the catalogue also records the reimbursement percentage. The maximum price is the legal cap — pharmacies may sell below it, so it is worth comparing the real price before you go. Latest import: 2026-11-03.

Data verified on from public sources (OpenStreetMap, chain websites, ANM/MS) — updated daily.

CANAMED catalogue

All medicines with Risankizumab

Maximum retail price = the legal selling cap. Sorted by price, lowest first.

Brand name Manufacturer Maximum price Reimbursement Prescription
SKYRIZI 360 mg ABBVIE DEUTSCHLAND GMBH & CO. KG - GERMANIA 10417.91 RON 100% · C1 (certain chronic diseases)
CNAS pays ~10417.91 RON; you ~0.00 RON*		 PR
SKYRIZI 600 mg ABBVIE S.R.L. - ITALIA 10417.91 RON 100% · C1 (certain chronic diseases)
CNAS pays ~10417.91 RON; you ~0.00 RON*		 PR
SKYRIZI 75 mg ABBVIE S.R.L. - ITALIA 13947.44 RON 100% · C1 (certain chronic diseases)
CNAS pays ~13947.44 RON; you ~0.00 RON*		 PR
SKYRIZI 180 mg ABBVIE DEUTSCHLAND GMBH & CO. KG - GERMANIA 22026.09 RON 100% · C1 (certain chronic diseases)
CNAS pays ~22026.09 RON; you ~0.00 RON*		 PR
SKYRIZI 150 mg ABBVIE S.R.L. - ITALIA — not reimbursed PR
SKYRIZI 150 mg ABBVIE S.R.L. - ITALIA — not reimbursed PR
SKYRIZI 55 mg ABBVIE S.R.L. - ITALIA — not reimbursed PR
SKYRIZI 75 mg ABBVIE S.R.L. - ITALIA — not reimbursed PR

Reimbursement and amounts come from the CNAS nomenclature (SIUI) valid in the current month, for each pack. *What you pay is indicative: the maximum price minus what CNAS pays on the main sublist, for an insured adult. The pharmacy may sell below the maximum price; low-income pensioners, children, pupils and pregnant women may pay less. C1 applies only to the diseases on the list, and C2 within the national programmes.

Prescription status key:

  • PR — With a medical prescription (PR)

Live pharmacy prices

Products with Risankizumab in our comparator

Shelf prices collected from the large chains — see on each product page where it is cheapest.

Good to know

How to read the maximum price

The CANAMED maximum retail price is the legal cap approved by the Ministry of Health — the pharmacy may sell for less, never for more. If the medicine is reimbursed, the sublist percentage (A 90%, B 50%, C1/C2 100%, D 20%) applies to the reference price of the therapeutic group, usually calculated from the cheapest product with the same INN — which is why your contribution can differ from one brand to another, even for the same active substance. The electronic prescription automatically shows the exact amount to pay; for non-prescription shelf prices, use the HartaFarmacii comparator.

CANAMED catalogue

Other active substances in the catalogue

See also the full list of reimbursed medicines, with an alphabetical index of all active substances.

Frequently asked questions

FAQ · Risankizumab

  1. Is Risankizumab reimbursed?
    Yes. For 4 of the catalogue entries with Risankizumab we have the reimbursement percentage on record. The percentage depends on the CNAS sublist each product is placed on (A 90%, B 50%, C1/C2 100%, D 20%) and applies to the reference price of the therapeutic group, not to the shelf price. Ask the doctor or pharmacist for the exact placement.
  2. What is the CANAMED maximum price for Risankizumab?
    The maximum retail prices (the CANAMED legal cap) for medicines with Risankizumab are between 10417.91 and 22026.09 RON. No pharmacy may sell above the maximum price, but it may sell below it — compare real prices with the HartaFarmacii comparator.
  3. What percentage of Risankizumab is reimbursed?
    The percentage depends on the CNAS sublist: A 90% (common chronic diseases), B 50% (partial reimbursement), C1 and C2 100% (serious chronic diseases and national programmes), D 20%. The percentage applies to the reference price set by CNAS, not to the shelf price, so you may pay a difference even for a “100% reimbursed” medicine. You can see the exact placement on the electronic prescription.
  4. How many medicines with Risankizumab are in the CANAMED catalogue?
    The CANAMED catalogue holds 8 authorised medicines with the active substance Risankizumab — different brand names, strengths and pharmaceutical forms. You will find them all, with maximum price and prescription status, in the table on this page. Latest CANAMED import into the HartaFarmacii database: 2026-11-03.

Before you go

Find the best price for Risankizumab

Compare prices →